Arena ADVISE - About the ADVISE Study

About the ADVISE Study

The ADVISE Study Is Enrolling Now!

For those with moderate-to-severe eczema, it can be incredibly discouraging finding a medication that works properly. The ADVISE Study is evaluating the effectiveness of an investigational medication, which would be taken orally, on those with moderate-to-severe eczema.

This study will last up to 20 weeks (4 week screening period, 12 week treatment, 4 week follow-up = 20 weeks) with each participant getting either a 1mg, 2mg dose of the study medication, or a placebo. The participants will take the drug once daily. 

It’s important for studies, like the ADVISE Study, to continue to research everything associated with this uncomfortable condition. There is still so much to learn about moderate-to-severe eczema and with each piece of information gathered,  we get closer to finding a more effective way to treat it.

If moderate-to-severe eczema is something you struggle with, consider joining the ADVISE Study now

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.